Advanced Solid Tumor Clinical Trials in Detroit, Michigan

16 studies are recruiting for advanced solid tumor in Detroit, Michigan right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A First-in-Human Study of YL217 in Patients With Advanced Solid Tumors

   A Phase 1 First-in-Human study of YL217 in Patients with Advanced Solid Tumors

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Karmanos Cancer Institute, Detroit, Michigan

   Locations

   21 in total

   Run by

   MediLink Therapeutics (Suzhou) Co., Ltd.

   See if you can join NCT06859762 on ClinicalTrials.gov

2. The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

   The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. The Phase 1 portion of the study will assess the safety, toler…

   Stage

   Phase 1

   Ages

   12 and older

   Site

   Karmanos Cancer Institute, Detroit, Michigan

   Locations

   77 in total

   Run by

   PMV Pharmaceuticals, Inc

   See if you can join NCT04585750 on ClinicalTrials.gov

3. BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors

   This is a dose escalation and dose expansion study to compare how well BGB-43395, a selective cyclin-dependent kinase 4 (CDK4) inhibitor, works as monotherapy or in combination with fulvestrant, letrozole, or elacestrant in participants with hormone receptor positive (HR+) and human epidermal growt…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Karmanos Cancer Institute, Detroit, Michigan

   Locations

   62 in total

   Run by

   BeOne Medicines

   See if you can join NCT06120283 on ClinicalTrials.gov

4. A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors

   This study will evaluate the safety, efficacy, optimal dose, and pharmacokinetics (PK) of BNT326 as monotherapy (Part 1) and as combination treatment with immunotherapeutic agents (Part 2) in participants with histologically or cytologically confirmed solid tumors that are advanced (i.e., either me…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Brigitte Harris Cancer Pavilion BHCP, Detroit, Michigan

   Locations

   76 in total

   Run by

   BioNTech SE

   See if you can join NCT07070232 on ClinicalTrials.gov

5. Study of SGN1 in Patients With Advanced Solid Tumor

   Objectives:To assess the safety and tolerability followed by a dose expansion study to characterize safety, and preliminary efficacy of SGN1 in participants with refractory solid tumors. Study Rationale:The mechanism of action for SGN1 is based on the fact that most tumors are methionine dependent.…

   Stage

   Phase 1

   Ages

   18 to 75

   Site

   Barbara Ann Karmanos Cancer Hospital dba Karmanos Cancer Center, Detroit, Michigan

   Locations

   8 in total

   Run by

   Guangzhou Sinogen Pharmaceutical Co., Ltd

   See if you can join NCT05038150 on ClinicalTrials.gov

6. Safety, Pharmacokinetics, and Efficacy of AI-081, a Bispecific Antibody for PD-1 And VEGF in Advanced Solid Tumors

   BIPAVE-001 is a Phase 1-2 study for evaluating the safety, pharmacokinetics (PK), and efficacy of AI-081 in solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Henry Ford Health, Detroit, Michigan

   Locations

   21 in total

   Run by

   OncoC4, Inc.

   See if you can join NCT06635785 on ClinicalTrials.gov

7. Metformin Combined With Chemotherapy and/or Immunotherapy in Solid Malignancies

   The goal of this clinical trial is to evaluate the safety of Metformin alone and in combination with chemotherapy or immunotherapy in patients with solid tumor cancers. The main questions it aims to answer are: * what are the toxicities of metformin at multiple dose levels * what is the maximum tol…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Karmanos Cancer Institute, Detroit, Michigan

   Locations

   10 in total

   Run by

   Barbara Ann Karmanos Cancer Institute

   See if you can join NCT07098299 on ClinicalTrials.gov

8. Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors

   This Phase 1, multi-center, open-label, dose escalation and dose optimization study is designed to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and preliminary clinical activity of MOMA-341 administered orally as a single agent or combination therapy in patients w…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Investigative Site #120, Detroit, Michigan

   Locations

   15 in total

   Run by

   MOMA Therapeutics

   See if you can join NCT06974110 on ClinicalTrials.gov

9. A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors

   The main purpose of this study is to evaluate the safety and preliminary efficacy of CHS-114 in combination with toripalimab and/or other standard of care (SOC) compound(s) in participants with advanced or metastatic solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Henry Ford Health System, Detroit, Michigan

   Locations

   30 in total

   Run by

   Coherus Oncology, Inc.

   See if you can join NCT06657144 on ClinicalTrials.gov

10. A Study of YL201 in Patients With Advanced Solid Tumors

    This is a phase 1, multicenter, nonrandomized, open-label, first-in-human study of YL201 conducted in China and the United States. The study will include 2 parts: a dose escalation part (Part 1) followed by a dose expansion part (Part 2). Part 1 will estimate the MTD/RED(s) in dose escalation cohor…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    007, Detroit, Michigan

    Locations

    45 in total

    Run by

    MediLink Therapeutics (Suzhou) Co., Ltd.

    See if you can join NCT05434234 on ClinicalTrials.gov

11. A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors

    This study investigates the safety and tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of EIK1003 in participants with advanced solid tumors.

    Stage

    Phase 1

    Ages

    18 to 89

    Site

    Karmanos Cancer Institute, Detroit, Michigan

    Locations

    57 in total

    Run by

    Eikon Therapeutics

    See if you can join NCT06253130 on ClinicalTrials.gov

12. Study of Ifinatamab Deruxtecan (DS-7300a, I-DXd) in Participants With Advanced Solid Malignant Tumors

    This is a single group study of participants with advanced solid tumors who have not been cured by other treatments. It is the first time the drug will be used in humans, and will be in two parts. The primary purpose of the parts are: * Dose Escalation Part: To evaluate the safety and tolerability …

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Henry Ford Hospital, Detroit, Michigan

    Locations

    28 in total

    Run by

    Daiichi Sankyo

    See if you can join NCT04145622 on ClinicalTrials.gov

13. A Study of DB-1310 in Advanced/Metastatic Solid Tumors

    This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1310 in subjects with advanced solid tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Henry Ford Health System, Detroit, Michigan

    Locations

    24 in total

    Run by

    DualityBio Inc.

    See if you can join NCT05785741 on ClinicalTrials.gov

14. FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Solid Tumors

    This is a phase 1 study designed to evaluate the safety, tolerability, and antitumor activity of FT825 (also known as ONO-8250) with or without monoclonal antibody therapy following chemotherapy in participants with advanced human epidermal growth factor receptor 2 (HER2)-positive or other advanced…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Karmanos Cancer Institute, Detroit, Michigan

    Locations

    14 in total

    Run by

    Fate Therapeutics

    See if you can join NCT06241456 on ClinicalTrials.gov

15. Study of SGR-3515 In Participants With Advanced Solid Tumors.

    The purpose of this study is to learn about the effects of a new study drug, called SGR-3515 that may be a treatment for advanced solid tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Karmanos Cancer Institute, Detroit, Michigan

    Locations

    14 in total

    Run by

    Schrödinger, Inc.

    See if you can join NCT06463340 on ClinicalTrials.gov

16. A Beta-only IL-2 ImmunoTherapY Study

    This is a Phase 1/2, multi-center, open-label, dose-escalation and expansion study to evaluate safety and tolerability, PK, pharmacodynamic, and early signal of anti-tumor activity of MDNA11 alone or in combination with a checkpoint inhibitor in patients with advanced solid tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Karmanos Cancer Institute, Detroit, Michigan

    Locations

    27 in total

    Run by

    Medicenna Therapeutics, Inc.

    See if you can join NCT05086692 on ClinicalTrials.gov